Study of XNW28012 in Subjects With Metastatic Pancreatic Cancer Who Received Prior Systemic Therapy
A phase 3 trial of XNW28012 for injection in pancreatic ductal adenocarcinoma, run by Evopoint Biosciences Inc., now recruiting.
Overview
Study of XNW28012 in Subjects With Metastatic Pancreatic Cancer Who Received Prior Systemic Therapy is a phase 3 interventional study registered as NCT07823049 by Evopoint Biosciences Inc., with 226 participants planned, started 2025-07-08 and due to reach its primary completion in 2027-05-31. Interventions recorded: XNW28012 for injection and XNW28012 Mimetic for Injection.
Similar pages
not linked directly; found by shared links- TrialStudy of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments
Shares Evopoint Biosciences, Pancreatic ductal adenocarcinoma and the tag pipeline.
- TrialA Study of PARG Inhibitor XNW29016 in Patients With Advanced Solid Tumors Who Failed Standard Treatment
Shares Evopoint Biosciences and the tag pipeline.
- TrialGlufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer
Shares Pancreatic ductal adenocarcinoma and the tag pipeline.
- TrialA Pivotal Study of Safety and Effectiveness of NanoKnife IRE for Stage 3 Pancreatic Cancer
Shares Pancreatic ductal adenocarcinoma and the tag pipeline.
- TrialACCENT: AMP945 in Combination With Nab-paclitaxel and Gemcitabine for Treatment of Pancreatic Cancer
Shares Pancreatic ductal adenocarcinoma and the tag pipeline.
- TrialFOLFIRINOX Versus OncoSil™ in Addition to FOLFIRINOX in Patients With Locally Advanced Pancreatic Adenocarcinoma
Shares Pancreatic ductal adenocarcinoma and the tag pipeline.
- TrialAcoustic Cluster Therapy (ACT) With Chemotherapy for the Treatment of Locally Advanced Pancreatic Cancer
Shares Pancreatic ductal adenocarcinoma and the tag pipeline.
- TrialThe Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer
Shares Pancreatic ductal adenocarcinoma and the tag pipeline.